NEW YORK (GenomeWeb News) – Proteome Sciences said today that it will collaborate with CHDI Foundation on research into protein biomarkers for Huntington's disease.

Under the collaboration, the London-based company will use its Tandem Mass Tag reagents to develop mass spectrometry-based high density protein expression maps in cell lines carrying different levels of the CAG-repeat genetic alteration linked to Huntington's.

The work will be done at Proteome Sciences' ISO 9001:2008 certified facility in Frankfurt. Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.